DLA Piper has advised Marinomed Biotech on the sale of its Carragelose business to Unither Pharmaceuticals. Lamartine Conseil reportedly advised Unither Pharmaceuticals.
Unither Pharmaceuticals is a French contract development and manufacturing organization.
According to DLA Piper, Carragelose, a sulfated polymer derived from red seaweed, is a unique, broadly active compound that blocks viruses and allergens.
Marinomed Biotech, headquartered in Korneuburg and listed on the Vienna Stock Exchange, is an Austrian biotech company known for the patent-protected Marinosolv platform, which enhances the solubility and bioavailability of poorly soluble compounds for the development of new therapeutics.
The DLA Piper team in Vienna included Partners Maria Doralt, Sabine Fehringer, Christian Temmel, Marc Lager, Dimitar Hristov, and Stephan Nitzl, Counsel Christian Knauder-Sima, Senior Associate Eric Wingert, and Junior Associates Christian Scheucher and Madeleine Albers.
